Related references
Note: Only part of the references are listed.Safety and Efficacy of Bosentan in Combination With Sildenafil in PAH Patients Who Experience Inadequate Clinical Response to Monotherapy: The COMPASS-3 Study
Raymond L. Benza et al.
CHEST (2011)
Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension A Randomized Controlled Clinical Trial
Vallerie V. McLaughlin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial (vol 149, pg 521, 2008)
G. Simonneau et al.
ANNALS OF INTERNAL MEDICINE (2009)
Tadalafil Therapy for Pulmonary Arterial Hypertension
Nazzareno Galie et al.
CIRCULATION (2009)
Diagnosis and Assessment of Pulmonary Arterial Hypertension
David B. Badesch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Updated Clinical Classification of Pulmonary Hypertension
Gerald Simonneau et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Ambrisentan for the treatment of pulmonary arterial hypertension -: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2
Nazzareno Galie et al.
CIRCULATION (2008)
Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial Hypertension A Randomized Trial
Gerald Simonneau et al.
ANNALS OF INTERNAL MEDICINE (2008)
Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility
Jayan Nagendran et al.
CIRCULATION (2007)
Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension
Vallerie V. McLaughlin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Renal hyporesponsiveness to brain natriuretic peptide: Both generation and renal activity of cGMP are decreased in patients with pulmonary hypertension
Anne Charloux et al.
PEPTIDES (2006)
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
M. M. Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
Sildenafil citrate therapy for pulmonary arterial hypertension
N Galiè et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy
HJ Seyfarth et al.
CHEST (2005)
Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension
D Ikeda et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2005)
Combination of bosentan with epoprostenol in pulmonary arterial hypertension:: BREATHE-2
M Humbert et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
MM Hoeper et al.
EUROPEAN RESPIRATORY JOURNAL (2004)
A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats
T Itoh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
HA Ghofrani et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension
HA Ghofrani et al.
ANNALS OF INTERNAL MEDICINE (2002)
Bosentan therapy for pulmonary arterial hypertension
LJ Rubin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension
C Rubens et al.
CHEST (2001)
Share Paper
